Latest Breaking News On - Lisa guiterman - Page 6 : comparemela.com

BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update

NEW YORK, May 9, 2023 /PRNewswire/ BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference. | May 9, 2023

United statesJohn mullalyStacy lindborgKirk taylorLisa guitermanChaim lebovitsBrainstorm cell therapeutics incLifesci advisorsCalifornia institute for regenerative medicinePrnewswire brainstorm cell therapeutics incDrug administrationNational ms societyEuropean medicines agencyStorm cell therapeuticsFirst quarterChief executive officer

BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.

United statesLisa guitermanSeanm healeyChaim lebovitsStacy lindborgJeffrey cohenJohn mullalyNational ms societyBrainstorm cell therapeutics incCalifornia institute for regenerative medicineCleveland clinic lerner college of medicineResearch summitEuropean medicines agencyMellen centerDrug administrationEuropean committee for treatment

Brainstorm Cell Therapeutics (BCLI) Announces FDA Advisory Committee Meeting to Review BLA for NurOwn

Brainstorm Cell Therapeutics (BCLI) Announces FDA Advisory Committee Meeting to Review BLA for NurOwn
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn mullalyBrian wallachStacy lindborgChaim lebovitsLisa guitermanBrainstorm coLifesci advisorsAdvisory committee meetingEuropean medicines agencyBrainstorm cell therapeutics incCalifornia institute for regenerative medicineDrug administrationNational ms societyStorm cell therapeuticsBiologics license application

BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.

United statesLisa guitermanBrian wallachChaim lebovitsJohn mullalyStacy lindborgNational ms societyCalifornia institute for regenerative medicineBrainstorm coLifesci advisorsAdvisory committee meetingBrainstorm cell therapeutics incEuropean medicines agencyDrug administrationBrainstorm cell therapeuticsBiologics license application

BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today.

United statesJohn mullalyDavid setbounChaim lebovitsLisa guitermanStacy lindborgCalifornia institute for regenerative medicineBrainstorm cell therapeutics incLifesci advisorsDrug administrationPrnewswire brainstorm cell therapeutics incNational ms societyEuropean medicines agencyStorm cell therapeuticsChief executive officerCo chief executive officer